Skip to main content
Erschienen in: Die Onkologie 6/2023

23.05.2023 | Mammakarzinom | CME

Adjuvante Strahlentherapie des Mammakarzinoms

verfasst von: Tim Lange, Anne Caroline Knöchelmann, Michael Bremer

Erschienen in: Die Onkologie | Ausgabe 6/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die adjuvante Strahlentherapie ist integraler Bestandteil der multimodalen Therapie des frühen Mammakarzinoms. Sie trägt über alle Erkrankungsstadien zur Reduktion von Lokalrezidiven bei. Die (moderat) hypofraktionierte Ganzbrustbestrahlung ist Behandlungsstandard. In der Niedrigrisikosituation kann eine Teilbrustbestrahlung erfolgen. Die Indikation zur adjuvanten Bestrahlung nach Mastektomie bzw. zu einer zusätzlichen Lymphabflussbestrahlung richtet sich nach dem jeweiligen Risikoprofil der Patientin. Langzeitergebnisse von Therapiestudien und die Weiterentwicklung von Bestrahlungstechniken ermöglichen heute zeitlich abgekürzte, individualisierte und gut verträgliche Behandlungen mit dem Ziel der Therapiedeeskalation.
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1701CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1701CrossRef
2.
Zurück zum Zitat Kunkler IH, Chir B, Williams LJ et al (2023) Breast-conserving surgery with or without irradiation in early breast cancer. N Eng J Med 388:385–394CrossRef Kunkler IH, Chir B, Williams LJ et al (2023) Breast-conserving surgery with or without irradiation in early breast cancer. N Eng J Med 388:385–394CrossRef
3.
Zurück zum Zitat Aalders C, Postma EL, Strobbe LJ et al (2016) Contemporary locoregional recurrence rates in young patients with early-stage breast cancer. J Clin Oncol 34:2107–2114CrossRefPubMed Aalders C, Postma EL, Strobbe LJ et al (2016) Contemporary locoregional recurrence rates in young patients with early-stage breast cancer. J Clin Oncol 34:2107–2114CrossRefPubMed
4.
Zurück zum Zitat Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms (2021). AWMF-Registernummer 032-45OL Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms (2021). AWMF-Registernummer 032-45OL
5.
Zurück zum Zitat McCormick B, Winter KA, Woodward W et al (2021) Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG oncology/RTOG 9804. J Clin Oncol 39:3574–3582CrossRefPubMedPubMedCentral McCormick B, Winter KA, Woodward W et al (2021) Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG oncology/RTOG 9804. J Clin Oncol 39:3574–3582CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bartelink H, Maingon P, Poortmans P et al (2015) European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16:47–56CrossRefPubMed Bartelink H, Maingon P, Poortmans P et al (2015) European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16:47–56CrossRefPubMed
7.
Zurück zum Zitat Coles C, Haviland JS, Kibry AM et al (2021) IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. Radiother Oncol 161(Suppl 1):S197–S199CrossRef Coles C, Haviland JS, Kibry AM et al (2021) IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. Radiother Oncol 161(Suppl 1):S197–S199CrossRef
8.
Zurück zum Zitat Vicini FA, Winter K, Freedman GM et al (2022) NRG/RTOG 1005: a phase III trial of hypofractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for hifh risk early-stage breast cancer. Int J Radiat Oncol Biol Physics. https://doi.org/10.1016/j.ijrobp.2022.07.2320CrossRef Vicini FA, Winter K, Freedman GM et al (2022) NRG/RTOG 1005: a phase III trial of hypofractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for hifh risk early-stage breast cancer. Int J Radiat Oncol Biol Physics. https://​doi.​org/​10.​1016/​j.​ijrobp.​2022.​07.​2320CrossRef
9.
Zurück zum Zitat Chua BH, Link EK, Kunkler ICH et al (2022) Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3‑07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet 400:431–440CrossRefPubMed Chua BH, Link EK, Kunkler ICH et al (2022) Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3‑07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet 400:431–440CrossRefPubMed
10.
Zurück zum Zitat Merten R, Fischer M, Kopytsia G et al (2023) Linac-based ultrahypofractionated partial breast irradiation (APBI) in low-risk breast cancer: first results of a monoinstitutional observational analysis. Cancers 15:1138–1148CrossRefPubMedPubMedCentral Merten R, Fischer M, Kopytsia G et al (2023) Linac-based ultrahypofractionated partial breast irradiation (APBI) in low-risk breast cancer: first results of a monoinstitutional observational analysis. Cancers 15:1138–1148CrossRefPubMedPubMedCentral
11.
12.
Zurück zum Zitat Kirby A (2018) Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial? Br J Radiol 91(1085):20170565CrossRefPubMedPubMedCentral Kirby A (2018) Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial? Br J Radiol 91(1085):20170565CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Offersen BV, Alsner J, Nielsen HM et al (2022) Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: The DBCG HYPO trial. J Clin Oncol 40:4189–4197CrossRefPubMed Offersen BV, Alsner J, Nielsen HM et al (2022) Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: The DBCG HYPO trial. J Clin Oncol 40:4189–4197CrossRefPubMed
14.
Zurück zum Zitat Strnad V et al (2023) Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol 24(3):262–272CrossRefPubMed Strnad V et al (2023) Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol 24(3):262–272CrossRefPubMed
15.
Zurück zum Zitat Hughes KS, Schnaper LA, Bellon J et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31:2382–2387CrossRefPubMedPubMedCentral Hughes KS, Schnaper LA, Bellon J et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31:2382–2387CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Whelan T, Smith S, Nielsen TO et al (2022) LUMINA: a prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol 40(17 Suppl):LBA501CrossRef Whelan T, Smith S, Nielsen TO et al (2022) LUMINA: a prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol 40(17 Suppl):LBA501CrossRef
18.
Zurück zum Zitat Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318:918–926CrossRefPubMedPubMedCentral Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318:918–926CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat De Wild SR, de Munck L, Simons JM et al (2022) De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5‑year follow-up results of a Dutch, prospective, registry study. Lancet Oncol 23:1201–1210CrossRefPubMed De Wild SR, de Munck L, Simons JM et al (2022) De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5‑year follow-up results of a Dutch, prospective, registry study. Lancet Oncol 23:1201–1210CrossRefPubMed
20.
Zurück zum Zitat Yeung R, Conroy L, Long K et al (2015) Cardiac dose reduction with deep inspiration breath hold for left-sided breast cancer radiotherapy patients with and without regional nodal irradiation. Clin Trial Radiat Oncol 10:200CrossRef Yeung R, Conroy L, Long K et al (2015) Cardiac dose reduction with deep inspiration breath hold for left-sided breast cancer radiotherapy patients with and without regional nodal irradiation. Clin Trial Radiat Oncol 10:200CrossRef
21.
Zurück zum Zitat Kim DY, Park E, Heo CY et al (2020) Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: toxicity analysis. Breast 55:37–44CrossRefPubMedPubMedCentral Kim DY, Park E, Heo CY et al (2020) Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: toxicity analysis. Breast 55:37–44CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Wang SL, Fang H, Song YW et al (2019) Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 20:352–360CrossRefPubMed Wang SL, Fang H, Song YW et al (2019) Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 20:352–360CrossRefPubMed
23.
Zurück zum Zitat Murray Brunt A, Haviland JS, Wheatley DA et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5‑year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395:1613–1626CrossRefPubMedPubMedCentral Murray Brunt A, Haviland JS, Wheatley DA et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5‑year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395:1613–1626CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Meattini I, Marrazzo L, Saieva C et al (2020) Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol 38(35):4175–4183CrossRefPubMed Meattini I, Marrazzo L, Saieva C et al (2020) Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol 38(35):4175–4183CrossRefPubMed
25.
Zurück zum Zitat Haviland JS, Owen JR, Dewar JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation Hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086–1094CrossRefPubMed Haviland JS, Owen JR, Dewar JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation Hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086–1094CrossRefPubMed
26.
Zurück zum Zitat Whelan TJ, Pignol JP, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513–520CrossRefPubMed Whelan TJ, Pignol JP, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513–520CrossRefPubMed
27.
Zurück zum Zitat Krug D, Vonthein R, Schreiber A et al (2021) Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlenther Onkol 197:802–811CrossRefPubMed Krug D, Vonthein R, Schreiber A et al (2021) Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlenther Onkol 197:802–811CrossRefPubMed
Metadaten
Titel
Adjuvante Strahlentherapie des Mammakarzinoms
verfasst von
Tim Lange
Anne Caroline Knöchelmann
Michael Bremer
Publikationsdatum
23.05.2023
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 6/2023
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-023-01357-2

Weitere Artikel der Ausgabe 6/2023

Die Onkologie 6/2023 Zur Ausgabe